Europe Biochip Market Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388044
  • Report
  • Region: Europe
  • 114 pages
  • Mordor Intelligence
1 of 4
A biochip is a collection of miniaturized test sites (microarrays) arranged on a solid substrate that permits many tests to be performed at the same time in order to achieve higher throughput and speed. Typically, a biochip's surface area is no larger than a fingernail. Like a computer chip that can perform millions of mathematical operations in one second, a biochip can perform thousands of biological reactions, such as decoding genes, in a few seconds.

The European biochip market was valued as a USD 1.3 billion in 2012. It is expected to become a USD 6.6 billion by 2018 thereby growing at a CAGR as high as 30.10%. This is a market to watch out for its great potential.

The biochip is basically segmented into three categories namely on the basis of products, applications and finally geography. The major factors which contributed to the growth of this market are increased application in cancer research, growth in personalized medicine and increased commercial application of biochips. The challenges faced by this market are low commercial acceptability due to higher costs, standardization issues and availability of alternate technologies.

From the geographical point of view, North America has the major chunk of the market share. In North America, USA market is the biggest. Following North America is Europe which has the next major market share. Biochip market has started recently in the emerging nations which have become an area where major investment is expected to happen which in turn helps in the growth of this market. In the APAC sector China and South Korea have been identified as potential emerging markets due to high R&D investments in the medical fields in recent times.

The major players in this biochip markets are Abbott Laboratories, Affymetrix,Inc , Agilent Technologies, Beckman Coulter, Biomeriuex, Biorad Laboratories, Roche Diagnostics, PerkinElmer and GE Healthcare.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1.INTRODUCTION
1.1 Report Description
1.2 Research Methodology
1.3 Stakeholders
2. EXECUTIVE SUMMARY
2.1 Key Findings
2.2 Market Overview
3. MARKET OVERVIEW
3.1 Market Defenition
3.1.1 Introduction
3.2 Market Segmentation
3.2.1 Products
3.2.2 Application
3.2.3 Geography
3.3 Market Drivers
3.3.1 Increasing application of Proteomics & Genomics in Cancer Research
3.3.2 Growth in personalized medicine
3.3.3 Regulatory approval for personalized medicine
3.3.4 Increased commercial application of Biochips
3.4 Market Limitations
3.4.1 Standardization
3.4.2 Low commercial acceptability due to the high costs
3.4.3 Availability of alternate technologies
3.4.4 Limites skilled population in the biochip market
4. EUROPEAN MARKETS : SEGMENTATION BY PRODUCT
4.1 DNA Microarrays
4.2 Lab on a chip/ Microfuidics
4.3 Protein Microarrays
4.4 Tissue Biochips
4.5 Carbohydrate Biochips
5. EUROPEAN MARKETS : SEGMENTATION BY APPLICATION
5.1 Gene Sequencing
5.2 Gene Expression
5.3 Cancer Research
5.4 Proteomics
5.5 Drug Discovery
5.6 Clinical Diagnosis
5.7 Genomics
5.8 Toxicogenomics
6. EUROPEAN MARKETS: SEGMENTATION BY GEOGRAPHY
6.1 UK
6.2 Germany
6.3 France
6.4 Spain
7. COMPETITIVE LANDSCAPE
7.1 Introduction
7.2Mergers & Acquisitions
7.3 Expansions
7.4 New Product Launch
7.5 Collaborations
8. COMPANY PROFILES
Biomerieux SA
Roche
Agendia
Oxford Gene Technologies
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll